Women Healthcare Market: Global Industry Analysis and Forecast (2023-2029)

The Global Women Healthcare Market size was valued at USD 15.8 Billion in 2022 and the total Women Healthcare revenue is expected to grow at a CAGR of 5.7% from 2023 to 2029, reaching nearly USD 23.29 Billion.
Global Women Healthcare Overview
The women healthcare market has witnessed substantial growth and evolution, driven by various factors shaping its current scenario, and recent development by key market players. Women healthcare encompasses a broad range of medical services and products specifically designed to address the unique health needs of women throughout their lives. It encompasses a wide spectrum of medical specialties, including gynaecology, obstetrics, reproductive medicine, endocrinology, and mental health. The primary factors driving growth include the rising chronic disease, and increasing health concerns in women.

To know about the Research Methodology :- Request Free Sample Report

The rising prevalence of chronic disease among women, increasing risk of cancer, driving the demand for new therapeutics for treatment, augmenting the women healthcare market's growth. In addition, the growing awareness of healthcare among the female population and rising product innovation all across the world are expected to be the further factors driving the demand for new therapeutics. Key players in this market have been actively involved in strategic development and acquisitions to enhance their portfolios and global reach. These collective efforts, including acquisition, technological advancement, and focus on healthcare strive to meet the growing demand for women healthcare market.
Women Healthcare Market Dynamics:
Expanding Access to Healthcare

The healthcare market is experiencing a lot of changes as far as healthcare access expansions are concerned. Thanks to technological advancement there are numerous ways in which healthcare access has been possible, such as telehealth refers to the provision of medical services using communication technology, these include video conferencing, telephone consultations, and remote monitoring. Telemedicine is much needed in rural and underprivileged areas where access to basic women healthcare is crucial but with the growing demand telemedicine is reaching out to rural and non-privileged communities, and people with restricted mobility or chronic conditions. With the access to technology on finger tips mHealth refers to the provision of healthcare using mobile phones, smartphones, and tablets, where health information, education, and tracking of health data are now done with apps and wearables.

Countries around the world are taking several steps to expand access to women healthcare, which includes increasing funding for women healthcare programs to provide a wide range of services, such as family planning, maternal and child health, and screening and treatment for cervical cancer and breast cancer. There are programs that countries are also providing education about contraception to women and their partners. Contraception is an essential part of women healthcare it allows women to control their fertility and prevent unintended pregnancies. Many countries are expanding access to contraception by making it more affordable and available. There is a shortage of healthcare providers who are trained in women healthcare this is particularly in rural and underserved areas.

Many countries are training more healthcare providers in women healthcare to access the care they need. Government, private, and international funding that boost the women healthcare market such as the World Health Organization (WHO) and United Nations Population Fund (UNFPA) provide funding in developing countries for family planning, maternal and child health, and screening and treatment for cervical cancer and breast cancer. Some programs are run in rural and under-privileged areas where they educate these women about diseases and give education on Women health. Empowering women is essential for improving their access to healthcare. This includes providing women with information about their health rights and options and encouraging them to seek care when they need it this increases demand for women healthcare market.

Impact of Chronic Diseases in the Women Healthcare Market

The Increasing prevalence of chronic diseases is a significant global health concern that is shaping the women healthcare market. Chronic diseases such as heart disease, cancer, diabetes, and respiratory-related diseases have now become the leading cause of death accounting for over 70% worldwide. The rising prevalence of these diseases is becoming common worldwide and they’re even leading to higher health care costs. However, the impact of chronic diseases is increasing in low and middle-income countries, where women face barriers to even accessing quality healthcare.

There has been a move from acute care to chronic care in the health care system, where chronic diseases require prolonged management and care as compared to acute diseases, which are characterized by short-term treatment. This is creating an upward demand for preventive, diagnostic, and treatment services for chronic diseases. There is an increasing need for new therapies for chronic disease, thanks to the pharmaceutical companies and biotechnologies companies investing in R&D for new drugs and therapies, which leads to a significant impact on the management of chronic diseases. Personalized medicine is a unique healthcare system that takes account of a patient’s genetic or other data before designing specific therapy programs. This personalized program helps attract consumers to seek treatments and grows awareness related to chronic diseases in the women healthcare sector. Technology is playing an important role in the management of chronic diseases, which includes an adaptation of telemedicine, mobile health apps, and wearable devices that improve patient engagement, provide remote monitoring, and facilitate data-driven decision-making. Technology is playing an important role in boosting the women healthcare market, as it is growing more focused on prevention and early detection, which can lead to better treatment outcomes and reduce the overall cost of care.



There is a growing need for collaboration between different stakeholders in the women healthcare system to address the challenges of chronic diseases, improving the quality of care for women and addressing the unique challenges they face. For example, the collaboration between the National Institute of Health (NIH), the US Food and Drug Administration, and private sector companies to promote research and development in women health. The patient-centred Outcomes Research Institute (PCORI) funded several projects on Women healthcare, including treatment for postpartum depression. This is an independent, non-profit organization that funds research that prioritizes patient-cantered outcomes. The National Women Health Network advocates for women health issues and has worked on a variety of issues, including access to preventive care, reproductive health, and mental health. The increasing prevalence of chronic diseases is a significant challenge, but it is also an opportunity for innovation and transformation in the women healthcare market.
Women Healthcare Market Segment Analysis:
Based on Drug, the women healthcare market is segmented into Prolia, XGEVA, EVISTA, Mirena, Zometa, Reclast or Aclasta, Minastrin 24 Fe, FORTEO, NuvaRing, Primarin, ACTONEL, and ORTHO TRI-CY LO (28). Prolia is the fastest-growing segment of the women healthcare industry accounting for the largest share of the market in 2022. Prolia and XGEVA are both antibodies that target RANKL, a protein that plays a role in bone restoration. The increasing demand for Prolia and XGEVA thanks to the treatment of osteoporosis among women and it has been studied for treating other conditions, such as multiple myeloma and cancer-related bone pain is the major factor responsible for the growth of this market.



EVISTA acts like estrogen in some tissues and anti-estrogen in others this is used to treat and prevent postmenopausal osteoporosis, which makes this segment used in multiple treatments and also it is being studied for the prevention of breast cancer. Mirena is a hormonal IUD that is highly effective in preventing pregnancy it is also used to treat heavy menstrual bleeding. Zometa is a medication used to treat a variety of bone conditions, including osteoporosis, multiple myeloma, and Paget's disease. It is also used to prevent hyperkalaemia, a condition in which there is too much calcium in the blood. Zometa works by slowing down the breakdown of bone, which helps to prevent bone fractures. The increasing demand for minimally invasive procedures and the growing adoption of telemedicine drive the women healthcare market.
Women Healthcare Market Regional Insights:
North America dominated the global women healthcare market with the highest market share of about 40% in 2022. The region is expected to maintain its trends throughout the forecast period. The increasing target population of women healthcare across the region is expected to be the primary growth factor driving the regional market growth. In addition, the rising prevalence of chronic diseases, the increasing demand for minimally invasive procedures, and the growing adoption of telemedicine, etc. are further contributing to the market growth.

The rising clinical trials and research and development activities in North America are expected to support the women healthcare market revenue growth. For example, the National Cancer Institute (NCI) at the National Institutes of Health (NIH) provides funding for research on Women cancers, including breast cancer, ovarian cancer, and cervical cancer. Additionally, The Planned Parenthood Federation of America provides funding for family planning, reproductive health care, and sexual education.

The U.S. is expected to lead the regional market by 2029 due to increasing research and product development activities, increasing patient population, governmental initiatives to increase awareness of women health, etc. According to the MMR analysis, there are 65% of women worldwide are not been able to seek help or belong to an underprivileged area experiencing zero help. This high prevalence of healthcare is driving the demand for new therapeutics and contributing to women healthcare market growth in the country.

The European women healthcare market represents a significant segment of the healthcare industry, encompassing a comprehensive range of services and products tailored to address the unique health needs of women throughout their lives. Europe's healthcare landscape is characterized by a diverse mix of public and private healthcare systems, varying levels of healthcare spending, and a strong commitment to evidence-based medicine. The market is driven by factors such as an aging population, the rising prevalence of chronic diseases among women, and increasing demand for minimally invasive procedures. Technological advancements and the adoption of digital health solutions are also expected to play a significant role in shaping the future of women healthcare in Europe.

Women Healthcare Market Competitive Landscapes

The Global Women Healthcare market is expected to be highly competitive active presence of numerous market players. Major companies are striving to introduce cost-efficient and advanced technological advanced products to meet the increasing demand, consequently fostering overall market growth. In addition, the Women Healthcare industry's growth is significantly influenced by research institutions and government backing for product approvals and technological advancements. Key players are adopting various business strategies, including technical partnerships and mergers and acquisitions (M&A) to remain competitive in the Women Healthcare market. For instance,

• Carlyle and PAI Partners acquire Theramex, a global specialty pharmaceuticals company focused on Women health in 2023
• AbbVie acquires Cahela Health, a developer of innovative Women health therapies in 2022
• Merck acquires Organon, a biopharmaceutical company specializing in Women health and fertility treatments in 2021
• Pfizer acquired Upjohn, a pharmaceutical company with a strong portfolio of Women health products in 2020
• Johnson & Johnson acquires Zaraz Pharmaceuticals, a developer of novel contraceptives in 2019
Women Healthcare Market Scope: Inquire Before Buying



Global Women Healthcare Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 15.8 Bn.


Forecast Period 2023 to 2029 CAGR:
5.7%
Market Size in 2029:
US $ 23.29 Bn.


 Segments Covered:
by Drug
Prolia
XGEVA
EVISTA
Mirena
Zometa
Other


by Application
Hormonal Infertility
Postmenopausal Osteoporosis
Endometriosis
Contraception
Polycystic Ovary Syndrome (PCOS)
Menopause
Other



Women Healthcare Market by Region:
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and the Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Women Healthcare Market Key Players:
1) AbbVie, Inc
2) Bayer AG
3) Merck & Co., Inc
4) Pfizer, Inc
5) Lupin
6) Teva Pharmaceutical Industries Ltd
7) Agile Therapeutics
8) Amgen, Inc
9) Apothecus Pharmaceutical
10) Blairex Laboratories, Inc.
11) Ferring Pharmaceuticals
12) Siemens
13) Hologic, Inc
14) Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
15) Abbott
16) Mylan N.V.
17) Allergan
18) F. Hoffmann-La Roche Ltd
19) Thermo Fisher Scientific Inc.
20) Koninklijke Philips N.V.
21) NeuroLogica Corp
22) Shimadzu Medical pvt. Ltd
23) GENERAL ELECTRIC
24) Quest Diagnostics Incorporated
25) Sysmex India Pvt. Ltd
26) Hitachi, Ltd
27) Canon Inc
28) FUJIFILM Holdings Corporation

FAQs:

1. What is the size of the women healthcare market?
Ans. The global Women healthcare market was estimated to be worth USD 15.8 billion in 2022 and is expected to reach USD 23.29 billion by 2029, at a CAGR of 5.7%.

2. What are the key drivers of the women healthcare market?
Ans. The increasing prevalence of chronic diseases among women, The rising healthcare expenditure, The growing awareness about preventive healthcare, The increasing demand for minimally invasive procedures, The growing adoption of telemedicine

3. What are the challenges facing the women healthcare market?
Ans. High healthcare costs
Limited access to healthcare services in some areas
Shortages of healthcare providers in some specialties
Disparities in access to care for women of color and low-income women
Lack of awareness about preventive care
Stigma surrounding mental health

4. Which segment accounted for the largest women health market share?
Ans. The contraceptives segment accounted for the largest share of more than 35.49% of the Women health market in 2022, due to the growing awareness regarding the usage of contraceptives, favorable reimbursement policies, and rising government and non-profit organization initiatives.

5. What are the factors driving the women health market?
Ans. An increase in the population of women aged over 60, a rise in unhealthy lifestyle habits, the introduction of novel medicines for Women health, and the impending approval of pipeline products are some of the factors that drive market growth